Lipocine Inc.(LPCN)Stock Analysis

LPCN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Lipocine Inc. (LPCN), a Healthcare sector company. LPCN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $16.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Lipocine Inc. reports quarterly revenue of $119.4K, net income of $-3.7M, free cash flow of $-2.3M. Top institutional holders of LPCN by reported 13-F value include Ikarian Capital,, Squadron Capital Management, Eversept Partners,, based on the most recent SEC filings. LPCN trades on the Nasdaq exchange and files with the SEC under CIK 1535955. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LPCN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lipocine Inc. directly from SEC EDGAR.